Comparative effectiveness of sodium–glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors on all-cause mortality in type 2 diabetes: a multinational propensity score–matched cohort study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.513 95% CI 0.502–0.525Authors' conclusion
SGLT2is were consistently associated with significantly lower all-cause mortality than DPP-4is.
Study context
- Population
- Adults aged >18 years with T2D initiating a SGLT2i or DPP-4i after ≥12 months of continuous therapy; TriNetX electronic health records (2015–2019)449,295 eligible
- Participants
- 161,950 vs 161,950
- Exposure
- SGLT2i vs DPP-4i
- SGLT2in = 161,950
- DPP-4in = 161,950reference
- Outcome
- All-cause mortality
- Follow-up
- 5 years
Methodological detailsmultinational, active-comparator, new-user, propensity-score matched (1:1 nearest neighbor), external validation
- Multinational
- Active-comparator
- New-user
- Propensity-score matched (1:1 nearest neighbor)
- External validation
Main finding
As reported in the abstract
Hazard ratio
0.513
95% CI 0.502–0.525
P < 0.001
Events by group
SGLT2ivs DPP-4i
HR 0.513 (95% CI 0.502–0.525); P < 0.001
Observational data: associations, not effects.
Further findings
Subgroups (sex, age, baseline glycemic control)
- Consistent reductions in mortality across sex, age categories and baseline glycemic control levels
External validation (Hong Kong/Singapore cohort)
- External validation confirmed improved survival with SGLT2i therapy
Original publication
Comparative effectiveness of sodium–glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors on all-cause mortality in type 2 diabetes: a multinational propensity score–matched cohort study. Diabetes Metab. Published 4 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →